Harmony Biosciences logo

Harmony Biosciences

HRMY | NASDAQ
Chart Builder DCF Calculator
$32.96
-$0.80 (-2.37%)
At close: Nov 16, 2026, 4:00 PM ET
$32.96
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.37%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
79
+1.0 pts
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #26/1021 (Top 3%)

Key Statistics

Market Data

Market Cap $1.94B
1D Range
32.87 34.01
52W Range
26.54 42.86

Valuation (TTM)

PE 10.91
PB 1.81
EV/EBITDA 4.84

Valuation (NTM)

Forward PE 9.10
Forward PEG 0.69
Price Target $49.00
Loading financial charts...

Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological cond...

Sector Healthcare
Industry Biotechnology
Employees 293
IPO Date Aug 19, 2020
Fiscal Year January - December

Latest News

HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

11 days ago · zacks.com

HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript

12 days ago · seekingalpha.com

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript
Harmony Biosciences Q3 Earnings Call Highlights

13 days ago · marketbeat.com

Harmony Biosciences Q3 Earnings Call Highlights
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates

13 days ago · zacks.com

Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

20 days ago · zacks.com

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
HRMY or ARGX: Which Is the Better Value Stock Right Now?

26 days ago · zacks.com

HRMY or ARGX: Which Is the Better Value Stock Right Now?
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?

26 days ago · zacks.com

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences

26 days ago · barrons.com

Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences
Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It

27 days ago · seekingalpha.com

Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

28 days ago · globenewswire.com

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

Earnings

Latest Earnings
Nov 4, 2026
EPS
$0.81
Miss -25.69%
REV
$268.92M
Miss -1.15%
Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Hold
Price Target
$49.00
Upside
+48.67%
Buy (3)
Hold (3)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.